Kimberly-Clark completed a $48.7 billion acquisition deal with Kenvue, a spin-off from Johnson & Johnson that manufactures consumer health products including Tylenol. Kimberly-Clark’s acquisition of ...

Kirk Perry, Kenvue CEO, says that the combined strengths of Kenvue and Kimberly-Clark will "empower us to innovate even faster and stronger", but there are concerns that the deal could pose further ...

The fall in Kimberly-Clark’s stock continued for a second day and raised the prospect that an activist investor could surface and try to block its merger-of-equals deal with Tylenol maker Kenvue.

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO’s ...

Consumer giant Kimberly-Clark, which makes Huggies diapers and Kleenex tissues, is buying the company that makes Tylenol and Band-Aids in one of the biggest mergers of the year. The deal, worth almost ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

(AP) - Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Kenvue shareholders will receive $3.50 per ...